<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818479</url>
  </required_header>
  <id_info>
    <org_study_id>HCI61077</org_study_id>
    <nct_id>NCT01818479</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies</brief_title>
  <official_title>Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, dose finding trial to assess the efficacy of Treg/Tcon addback to partially
      matched related donor stem cells. The maximum tolerated dose will be established using 3
      subjects per dose level, with an expansion cohort at the maximum tolerated dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute GVHD</measure>
    <time_frame>36 months</time_frame>
    <description>Rate of acute GVHD grade III-IV at Day +100 post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Engraftment</measure>
    <time_frame>36 months</time_frame>
    <description>Day +28 and +100 neutrophil engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at Day 100</measure>
    <time_frame>36 months</time_frame>
    <description>Day +100 and one year survival Day +100 and one year transplant related mortality Day +100 and one year relapse rates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>High Risk Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>stem cell transplant</intervention_name>
    <description>Open label, dose finding trial with two treatment regimens, Busulfan and TBI with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell transplant</intervention_name>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Age 0-70 years 2. Karnofsky or Lansky Performance status &gt;70% 3. High risk hematologic
        malignancy 4. Acute myeloid leukemia (AML) with one or more of the following criteria:
        4a.Poor risk cytogenetics, including -5, 5q-, -7, 7q-, t(9;22); complex cytogenetics (&gt;3
        abnormalities); or normal cytogenetics with Flt3 ITD, in first or subsequent complete
        remission (CR).

        4b. Relapsed or primary refractory AML with &lt;10% blasts in the peripheral blood.

        4c. Subjects in CR1 who required two cycles of induction to achieve remission may be
        included at the discretion of the treating physician.

        4d. Standard risk or intermediate risk cytogenetics in second or subsequent CR (enrolled at
        the discretion of the treating physician).

        5. Acute lymphoblastic leukemia (ALL) with one of the following criteria: 5a. Second or
        subsequent CR 5b. Any PR (no circulating blasts) 5c. High-risk ALL in first CR including
        (Ph+, t(4:11), complex karyotype, hypodiploidy (&lt;44 chromosomes), or positive MRD after
        induction 6. Myelodysplasia, intermediate -2 (score 1.5-2.0) or high risk (score &gt;2.5) by
        the International Prognostic Score System.

        7. Myeloproliferative Disorders (include CMML, AMM or Idiopathic Myelofibrosis, and JMML)
        with excess blasts (&gt;5%) 8. Chronic myeloid leukemia (CML) with one of the following
        criteria: 8a. Second or subsequent chronic phase 8b. Accelerated phase 8c. blast crisis 9.
        Non-Hodgkin's lymphoma (NHL) meeting one of the following criteria: 9a. Relapse after
        autologous stem cell transplantation with evidence of responsive disease.

        9b. Subject with chemosensitive relapse who have no option for autologous stem cell
        transplantation due to blood or marrow involvement or failure to mobilize autologous stem
        cells or are not considered eligible for autologous transplant by their treating physician.

        9c. Hodgkin's Lymphoma: relapse after autologous HCT, chemo-refractory disease 9d. Multiple
        myeloma: per NCCN guidelines. Updated annually at: www.nccn.org 10. No suitable
        HLA-identical sibling donor. 11. No identified 8/8 (based upon A, B, C, DRB1 loci) allele
        matched unrelated donor, or unable to wait sufficient time to procure a 8/8 allele matched
        unrelated donor 12. Available HLA 3-5/6 matched genotypically haploidentical partially
        matched related donor 13. Female subjects must be surgically sterile, postmenopausal
        (minimum 1 year without menses), or agree to use approved form of contraception from the
        time of signing the informed consent form through Day +100. Male subjects must also agree
        to use an approved form of birth control for either themselves or their partner, as
        appropriate, from the time of signing the informed consent form through Day +100.

        14. Able to provide informed consent and have signed an approved consent form that conforms
        to federal and institutional guidelines.

        Exclusion Criteria:

          1. Available HLA identical matched sibling donor (unless having failed a prior allogeneic
             transplant from an HLA identical matched sibling)

          2. Recipient HLA antibodies against donor HLA

          3. Any of the following organ dysfunctions:

               1. Cardiac- left ventricular ejection fraction &lt;40%, symptomatic coronary artery
                  disease, or uncontrolled arrhythmias

               2. Pulmonary- FEV1 or DLco&lt;40% or need for use of supplemental oxygen

               3. Renal- calculated or measured GFR &lt;30 ml/min, dialysis requirement, or prior
                  renal transplant

               4. Hepatic- bilirubin &gt; 2.0, ALT&gt; 2.5 X ULN, cirrhosis

          4. Subjects with active or uncontrolled bacterial, viral, or fungal infections requiring
             systemic therapy.

          5. Subjects who have tested positive for HIV.

          6. Pregnant women, nursing mothers or women of child-bearing potential who are unwilling
             to use medically accepted methods of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kolleen Hicks</last_name>
    <phone>801-587-7604</phone>
    <email>Kolleen.Hicks@hci.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Pena</last_name>
    <phone>801-213-4233</phone>
    <email>karen.pena@hci.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

